In the News: The 22nd Anniversary of 9/11, Updated COVID-19 Vaccines Available Soon, Cancer Moonshot, and New Myeloma Research Findings
The week highlighted various crucial developments including the commemoration of the 9/11 anniversary with a growing number of cancer-related deaths among survivors and first responders due to toxic exposure, specifically linking increased cases of multiple myeloma to such exposures.
The World Trade Center Health Program findings revealed higher risks of specific blood conditions associated with gene mutations and clonal hematopoiesis due to toxins after 9/11, covering cases of MGUS, smoldering multiple myeloma, and multiple myeloma. A myeloma patient success story emphasized the potential connection between myeloma diagnosis and toxic exposure after 9/11, shedding light on the increased risk for those who worked in the World Trade Center area.
Additional highlights of this week’s news include an update on COVID-19 vaccines, insights from myeloma research, including new potential treatments and the use of bee glue in myeloma treatment, the FDA approval of Motixafortide for myeloma patients, and the Cancer Moonshot program’s significant investments and initiatives.